Kingdon Capital Management’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Kingdon Capital Management’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-66,665	Closed	-$2.2K	–	100
2023 Q1	$2.2K	Hold	66,665	–	–	﹤0.01%	57
2022 Q4	$3.54K	Hold	66,665	–	–	﹤0.01%	49
2022 Q3	$2K	Hold	66,665	–	–	﹤0.01%	59
2022 Q2	$2K	Hold	66,665	–	–	﹤0.01%	69
2022 Q1	$11K	Hold	66,665	–	–	﹤0.01%	82
2021 Q4	$36K	Hold	66,665	–	–	﹤0.01%	76
2021 Q3	$48K	Hold	66,665	–	–	0.01%	61
2021 Q2	$69K	Buy	+66,665	New	+$59.8K	0.01%	67

Kingdon Capital Management's EUCRW Position: Q2 2023 in Review

Kingdon Capital Management sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2023, closing a stake of 66,665 shares — an estimated $2.2K sold.

Kingdon Capital Management first reported a position in EUCRW in Q2 2021 and held it in 8 quarters. The position peaked at $69K in Q2 2021. 0 funds tracked by Wall St. Rank hold EUCRW as of Q2 2023.

Kingdon Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2023 after selling out during the quarter.
Kingdon Capital Management sold 66,665 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2023, an estimated $2.2K.
Kingdon Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q2 2021 and held it in 8 quarters.
Kingdon Capital Management's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $69K in Q2 2021.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2023.

Based on Kingdon Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.